Reasons for discontinuing intracavernous injection therapy with prostaglandin E1 (alprostadil)
- 1 February 1999
- Vol. 53 (2), 397-400
- https://doi.org/10.1016/s0090-4295(98)00478-6
Abstract
No abstract availableThis publication has 16 references indexed in Scilit:
- Long-term follow-up of patients receiving injection therapy for erectile dysfunctionUrology, 1997
- Treatment of Men with Erectile Dysfunction with Transurethral AlprostadilNew England Journal of Medicine, 1997
- Impotence and Its Medical and Psychosocial Correlates: Results of the Massachusetts Male Aging StudyJournal of Urology, 1994
- NIH Consensus Conference. Impotence. NIH Consensus Development Panel on ImpotenceJAMA, 1993
- Patient satisfaction with pharmacologic erection programUrology, 1992
- An Improved Vasoactive Drug Combination for a Pharmacological Erection ProgramJournal of Urology, 1991
- ImpotenceNew England Journal of Medicine, 1989
- Intracavernous Self-Injection for Impotence: A Long-Term Therapeutic Option? Experience In 78 PatientsJournal of Urology, 1988
- Intracavernous Drug-Induced Erections in the Management of Male Erectile Dysfunction: Experience with 100 PatientsJournal of Urology, 1986
- INTRACAVERNOUS INJECTION OF PAPAVERINE FOR ERECTILE FAILUREThe Lancet, 1982